A strategy for detecting optimal ratio of cardioprotection-dependent three compounds as quality control of Guan-Xin-Er-Hao formula

Experimental and Therapeutic Medicine

et al. 2013

Self Cite

Coronary heart disease (CHD) is the leading cause of mortality worldwide. The Chinese medicinal formula Guanxin II has been shown to have a favorable effect in the attenuation of angina. The aim of this study was to compare the pharmacokinetics of ferulic acid (FA), which is a vasorelaxant compound present in Guanxin II, in healthy volunteers and patients with angina pectoris following the administration of Guanxin II. Ex vivo experiments were performed in order to investigate the vasorelaxant effect of FA on the human internal mammary artery (IMA) to provide evidence that it is a bioactive component of Guanxin II. Following the oral administration of Guanxin II, the FA levels in the serum were quantified by a simple and rapid high-performance liquid chromatography (HPLC) method. Treatment with FA (10−8−10−3 M) caused a concentration-dependent relaxation of endothelial IMA rings following precontraction with KCl. Statistically significant differences were identified between the pharmaco-kinetic parameters Cmax, t1/2α, t1/2β and t1/2Ka of the healthy volunteers and the patients with angina pectoris following the oral administration of Guanxin II. FA is a bioactive compound absorbed from Guanxin II that attenuates angina pectoris, a condition that may modify the pharmacokinetics of FA. Not only do the pharmacokinetic parameters direct the clinical use of Guanxin II, but they may also be useful for exploring the pathology of angina pectoris.

Section: Introductionmentioning

confidence: 95%

Pharmacokinetic comparison of the vasorelaxant compound ferulic acid following the administration of Guanxin II to healthy volunteers and patients with angina pectoris

Huang

Experimental and Therapeutic Medicine

et al. 2013

Self Cite

“…For the first time, UPLC‐ESI‐MS/MS in the negative ionization and MRM modes provided a highly selective and sensitive method for determination of HSYA in the CSF, blood and urine of TBI patients (Figure ). The selection of UPLC conditions was guided by the need to obtain good resolution of HSYA in a shorter time (<3 min) than previous methods (Huang et al ., ; Wang et al ., ). Gradient elution was used to separate HSYA from interferences, and also to ensure that each run was completed in 3 min.…”

Section: Resultsmentioning

confidence: 97%

“…According to the current scientific consensus (Huang et al ., ; Wang et al ., ), bioactive compounds which exert pharmaceutical effects are first absorbed into the human body. However, whether and which anthraquinones contained in the five bioactive components of XBJ are absorbed by TBI patients remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Determination of hydroxysafflor yellow A in biological fluids of patients with traumatic brain injury by UPLC‐ESI‐MS/MS after injection of Xuebijing

Guo

Biomedical Chromatography

Huang

et al. 2014

Self Cite

A simple, novel, specific, rapid and reproducible ultra-performance liquid chromatography electrospray ionization tandem mass spectrometry method has been developed and validated for the determination of hydroxysafflor yellow A (HSYA) in biological fluids (plasma, urine and cerebrospinal fluid) of patients with traumatic brain injury after intravenous injection of Xuebijing (XBJ). Liquid-liquid extraction was performed, and separation was carried out on an Acquity UPLC™ BEH C18 column, with gradient elution using a mobile phase composed of methanol and 0.1% formic acid at a flow rate of 0.3 mL/min. A triple quadrupole tandem mass spectrometer with electrospray ionization was used for the detection of HSYA. The mass transition followed was m/z 611.0 → 491. The retention time was less than 3.0 min. The calibration curve was linear in the concentration range from 2 to 6125 ng/mL for cerebrospinal fluid, plasma and urine. The intra- and inter-day precisions were <10%, and the relative standard deviation of recovery was <15% for HSYA in biological matrices. The method was successfully applied for the first time to quantify HSYA in the biological fluids (especially in cerebrospinal fluid) of patients with traumatic brain injury following intravenous administration of XBJ.

“…Some scholars have introduced the best ratio of principal components in some CHM decoction and documented the influences of different decocting methods. These new research updates provide foundations for new experiments and assist in the establishment of standard CHM QC systems [9]. The degree of contribution of principal components in herbal medicine is still a high-profile and also a difficult topic in the CHM research field.…”

Section: Current Status On Material-based Chm Researchmentioning

confidence: 99%

New Perspectives on Specific Immune‐Depletion Technique Using Monoclonal Antibodies against Small Active Molecules in Herbs

Evidence-Based Complementary and Alternative Medicine

Cheng

et al. 2014

One of the main focuses in Chinese Medicine research is the identification of efficacious components in Chinese herbal medicine (CHM). Studies in such area are difficult due to the complexity and the synergistic characteristics of CHM. Current methods to track and separate active components are not adequate to meet the needs of revealing effects and identify substances and pharmacological mechanisms, which directly restrict the modernization and globalization of CHM. In this paper, a new methodology to deplete a single active component via immunoassay was introduced. The specific active component in a CHM mixture can then be identified and studied through comparative analyses of the pharmacological effects before and after immune depletion. With this new methodology, degree of contribution of a particular component to the whole complex herbal mixture can be elucidated, and its synergistic property with other components can be determined. The new method can reflect not only the overall combined pharmacological effects of CHM but also the effect of individual component. It is an effective way to explain the degree of contribution of one specific component to the overall activity of a CHM prescription.